Leading team of 4 Strategic Insights and Pricing managers tasked to drive above market growth of the $5Bn CSS franchise, including Biosense Webster (EP), Mentor (Breast Aesthetics/Recon.), and Cerenovus (Neurovascular). • Instituted processes and governance to manage price delivering $50MM above CSS’s 2022 price plan.• Oversaw CSS’s Strategic Insights support (including, market and share reporting, forecasting, competitive intelligence, decision support tools).• Commissioned research projects which inform pipeline investment and go-to-market decisions, including segmentation research, Net Promoter Score surveys, and pricing studies.

Led team of 7 platform pricing managers tasked to develop, implement, and oversee global pricing strategy, policies, and long-term capabilities across the MedTech’s portfolio of products with global gross sales of $23Bn. • Partnered with regions and franchises to improve annual price performance by $115 MM from 2019 - 2022.• Oversaw development and execution of brand ladders and price corridors, which limited price erosion to $150MM in 2020 ($110MM better than FY20 Business Plan).• Identified price optimization opportunities and supported organization’s attainment of 6X volume return on price investment in 2019 (highest multiple in 4 years).• Promoted value-based pricing principles and launch excellence tools to set pricing across all franchises contributing to more than $150 MM of incremental pipeline value over strategic horizon.

Led global pricing strategy of Ethicon’s $8 Bn product portfolio. • Championed pricing culture and competency development across Ethicon and the broader MD&D segment.• Managed pricing strategy development for more than 20 new product launches.• Led development of pricing strategy sections of MD Launch Excellence Process and as a coach trained more than 100 colleagues across the sector. • Promoted to lead Ethicon Global Pricing function in December 2016.• Selected to lead development of Wound Closure & Repair Platform Strategic Plan.

Directed US pricing strategy of Ethicon Surgical Care’s $2 Bn product portfolio. • Led multi-functional team to develop pricing and contract strategy response for all GPOs and revised Independent contracting strategy for Wound Closure and Hernia contracts. In the process, regained positions at all GPOs across product categories, which included strategic price increases.• Co-developed pricing course targeted to increase competency development within marketing team.• Selected to be interim Global Leader of Customer Value Pricing team and expanded pricing strategy from US pilot project to gold standard in global pricing strategy.• Co-led planning team and hosted 2012 MD&D Global Pricing and Contracting Summit, showcasing best pricing practices across more than a dozen JNJ operating companies.

Managed Channel Marketing initiatives including, pricing and contracting, digital marketing, and resident outreach for $1Bn, 10,000+ SKU portfolio of Wound Closure and Hernia Repair Products.• Led US Pricing Pilot for $700 MM suture portfolio resulting in $4MM of incremental price in 2011.

Led US Marketing of $130MM, 2000+ SKU portfolio of products, including Diagnostics (catheters, sheaths, and wires) and Interventional Devices (guiding catheters, steerable guidewires, and PTCA balloons).• Oversaw multi-functional team focused on restructuring the Core Product pricing and contracting strategy to leverage breadth of portfolio and increase revenue share.• Chartered global project to evaluate 3 catheter iteration opportunities for Global Strategic Marketing team. • Designed marketing collateral to reinvigorate legacy products and to deliver a more procedural-based sale.• Trained more than 150 sales representatives, clinical colleagues, and marketing associates by creating, recording, and developing sales training curriculum for Core Products.• Navigated Diagnostic business through extensive competitive backorder with minimal impact to patient care. As a result, converted 20% of the diverted demand resulting in $800K of sales in 3Q 2009.• Achieved 2009 Business Plan (BP) and surpassed 2008 BP by 2%.

Transitioned $25MM EVH platform from JNJ to Datascope, supporting acquisition outside traditional call point. • Launched newly acquired EVH business to regional marketing leaders and to US Cardiac Assist sales team.• Created justification for increased marketing resources and addition of Product Manager as a direct report. • Led cross-functional team to develop a multi-generation product development plan. • Launched the next generation EVH system to global marketers and to US sales force.• Managed national preceptor network and grew it by targeting competitive preceptors.• Outperformed US EVH BP by 11% in Fiscal Year 2006 and achieved Worldwide BP during same period.

Led US Marketing of CardioVation’s $13 MM EVH product portfolio with the goal of promoting EVH procedure as the “standard of care” for conduit harvesting in CABG surgery.• Planned CardioVations presence at major international cardiac surgery conventions including conceptualizing seminars and topics of focus and securing key opinion leaders.• Created hands-on professional education laboratory events for surgeons and physician assistants.• Grew Endoscopic Vessel Harvesting line to $13 MM in 2005 (13% increase).• Earned J&J’s “Standards of Leadership” Award for serving as a proxy for the Director of Sales Operations.

Managed teams of 10 researchers across 3 offices in efforts to prepare expert witness testimony in matters of antitrust in the Medical Device and Health Insurance industries. • Managed a 10-person research staff during extensive data collection and document discovery undertaken to gauge the market impact of the Aetna-Prudential merger, NERA’s second most profitable case in 1999.• Co-authored a pharmaco-economic study promoting the advantages of a newly patented drug over its generic competition in the treatment of pulmonary embolism. (Journal of Medical Economics).• Promoted three times during 5-year tenure.